# The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases

> **NCT05877001** · PHASE2 · UNKNOWN · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 20 (estimated)

## Conditions studied

- Colorectal Liver Metastases

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Regorafenib
- **OTHER:** HAIC

## Key facts

- **NCT ID:** NCT05877001
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-30
- **Primary completion:** 2024-07-30
- **Final completion:** 2025-03-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05877001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05877001, "The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05877001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*